Certain aryl and cycloalkyl fused imidazopyrazinediones; a new class of GABA brain receptor ligands
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Nov 30, 1993
Grant Date -
N/A
app pub date -
Apr 30, 1992
filing date -
Apr 30, 1992
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The present invention encompasses compounds of the formula: ##STR1## and the pharmaceutically acceptable non-toxic salts thereof wherein: where X represents hydrogen of lower alkyl; W represents an aryl group unsubstituted or substituted with various organic and inorganic substitutents; ##STR2## where A, B, C, D, and E represent carbon or nitrogen substituted with hydrogen or various organic and inorganic substituents; and n is 0, 1, or 2, Y, R.sub.3, R.sub.4, R.sub.12, and R.sub.13 are various organic and inorganic substituents. These compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs thereof and are useful in the diagnosis and treatment of anxiety, sleep, and seizure disorders, overdose with benzodiazepine drugs, and enhancement of memory.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully